Cargando…

Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues

To assess the prognostic and diagnostic utility of PSA immunostaining, tissue microarrays containing 17,747 prostate cancers, 3,442 other tumors from 82 different (sub) types and 608 normal tissues were analyzed at two different antibody concentrations (1:100 and 1:800). In normal tissues, PSA expre...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonk, Sarah, Kluth, Martina, Hube-Magg, Claudia, Polonski, Adam, Soekeland, Greta, Makropidi-Fraune, Georgia, Möller-Koop, Christina, Witt, Melanie, Luebke, Andreas M., Hinsch, Andrea, Burandt, Eike, Steurer, Stefan, Clauditz, Till S., Schlomm, Thorsten, Perez, Daniel, Graefen, Markus, Heinzer, Hans, Huland, Hartwig, Izbicki, Jakob R., Wilczak, Waldemar, Minner, Sarah, Sauter, Guido, Simon, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739211/
https://www.ncbi.nlm.nih.gov/pubmed/31534629
http://dx.doi.org/10.18632/oncotarget.27145
_version_ 1783450901753626624
author Bonk, Sarah
Kluth, Martina
Hube-Magg, Claudia
Polonski, Adam
Soekeland, Greta
Makropidi-Fraune, Georgia
Möller-Koop, Christina
Witt, Melanie
Luebke, Andreas M.
Hinsch, Andrea
Burandt, Eike
Steurer, Stefan
Clauditz, Till S.
Schlomm, Thorsten
Perez, Daniel
Graefen, Markus
Heinzer, Hans
Huland, Hartwig
Izbicki, Jakob R.
Wilczak, Waldemar
Minner, Sarah
Sauter, Guido
Simon, Ronald
author_facet Bonk, Sarah
Kluth, Martina
Hube-Magg, Claudia
Polonski, Adam
Soekeland, Greta
Makropidi-Fraune, Georgia
Möller-Koop, Christina
Witt, Melanie
Luebke, Andreas M.
Hinsch, Andrea
Burandt, Eike
Steurer, Stefan
Clauditz, Till S.
Schlomm, Thorsten
Perez, Daniel
Graefen, Markus
Heinzer, Hans
Huland, Hartwig
Izbicki, Jakob R.
Wilczak, Waldemar
Minner, Sarah
Sauter, Guido
Simon, Ronald
author_sort Bonk, Sarah
collection PubMed
description To assess the prognostic and diagnostic utility of PSA immunostaining, tissue microarrays containing 17,747 prostate cancers, 3,442 other tumors from 82 different (sub) types and 608 normal tissues were analyzed at two different antibody concentrations (1:100 and 1:800). In normal tissues, PSA expression was limited to prostate epithelial cells. In prostate cancers, PSA staining was seen in 99.9–100% (1:800–1:100) primary tumors, 98.7–99.7% of advanced recurrent cancers, in 84.6–91.4% castration resistant cancers, and in 7.7–18.8% of 16 small cell carcinomas. Among extraprostatic tumors, PSA stained positive in 0–3 (1:800-1:100) of 19 osteosarcomas, 1-2 of 34 ovarian cancers, 0-2 of 35 malignant mesotheliomas, 0–1 of 21 thyroid gland carcinomas and 0–1 of 26 large cell lung cancers. Reduced staining intensity and loss of apical staining were strongly linked to unfavorable tumor phenotype and poor prognosis (p < 0.0001 each). This was all the more the case if a combined “PSA pattern score” was built from staining intensity and pattern. The prognostic impact of the “PSA pattern score” was independent of established pre- and postoperative clinico-pathological prognostic features. In conclusion, PSA immunostaining is a strong prognostic parameter in prostate cancer and has high specificity for prostate cancer at a wide range of antibody dilutions.
format Online
Article
Text
id pubmed-6739211
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-67392112019-09-18 Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues Bonk, Sarah Kluth, Martina Hube-Magg, Claudia Polonski, Adam Soekeland, Greta Makropidi-Fraune, Georgia Möller-Koop, Christina Witt, Melanie Luebke, Andreas M. Hinsch, Andrea Burandt, Eike Steurer, Stefan Clauditz, Till S. Schlomm, Thorsten Perez, Daniel Graefen, Markus Heinzer, Hans Huland, Hartwig Izbicki, Jakob R. Wilczak, Waldemar Minner, Sarah Sauter, Guido Simon, Ronald Oncotarget Research Paper To assess the prognostic and diagnostic utility of PSA immunostaining, tissue microarrays containing 17,747 prostate cancers, 3,442 other tumors from 82 different (sub) types and 608 normal tissues were analyzed at two different antibody concentrations (1:100 and 1:800). In normal tissues, PSA expression was limited to prostate epithelial cells. In prostate cancers, PSA staining was seen in 99.9–100% (1:800–1:100) primary tumors, 98.7–99.7% of advanced recurrent cancers, in 84.6–91.4% castration resistant cancers, and in 7.7–18.8% of 16 small cell carcinomas. Among extraprostatic tumors, PSA stained positive in 0–3 (1:800-1:100) of 19 osteosarcomas, 1-2 of 34 ovarian cancers, 0-2 of 35 malignant mesotheliomas, 0–1 of 21 thyroid gland carcinomas and 0–1 of 26 large cell lung cancers. Reduced staining intensity and loss of apical staining were strongly linked to unfavorable tumor phenotype and poor prognosis (p < 0.0001 each). This was all the more the case if a combined “PSA pattern score” was built from staining intensity and pattern. The prognostic impact of the “PSA pattern score” was independent of established pre- and postoperative clinico-pathological prognostic features. In conclusion, PSA immunostaining is a strong prognostic parameter in prostate cancer and has high specificity for prostate cancer at a wide range of antibody dilutions. Impact Journals LLC 2019-09-10 /pmc/articles/PMC6739211/ /pubmed/31534629 http://dx.doi.org/10.18632/oncotarget.27145 Text en Copyright: © 2019 Bonk et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Bonk, Sarah
Kluth, Martina
Hube-Magg, Claudia
Polonski, Adam
Soekeland, Greta
Makropidi-Fraune, Georgia
Möller-Koop, Christina
Witt, Melanie
Luebke, Andreas M.
Hinsch, Andrea
Burandt, Eike
Steurer, Stefan
Clauditz, Till S.
Schlomm, Thorsten
Perez, Daniel
Graefen, Markus
Heinzer, Hans
Huland, Hartwig
Izbicki, Jakob R.
Wilczak, Waldemar
Minner, Sarah
Sauter, Guido
Simon, Ronald
Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues
title Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues
title_full Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues
title_fullStr Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues
title_full_unstemmed Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues
title_short Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues
title_sort prognostic and diagnostic role of psa immunohistochemistry: a tissue microarray study on 21,000 normal and cancerous tissues
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739211/
https://www.ncbi.nlm.nih.gov/pubmed/31534629
http://dx.doi.org/10.18632/oncotarget.27145
work_keys_str_mv AT bonksarah prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT kluthmartina prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT hubemaggclaudia prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT polonskiadam prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT soekelandgreta prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT makropidifraunegeorgia prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT mollerkoopchristina prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT wittmelanie prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT luebkeandreasm prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT hinschandrea prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT burandteike prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT steurerstefan prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT clauditztills prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT schlommthorsten prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT perezdaniel prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT graefenmarkus prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT heinzerhans prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT hulandhartwig prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT izbickijakobr prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT wilczakwaldemar prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT minnersarah prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT sauterguido prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues
AT simonronald prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues